I don't do well beyond very basic conversational German.
In Reply to 'FarmaZutical'
German analysis of Clinuvel's potential. Very well written and levelheaded. I still think, though, that the author sets the number of EPP patients far too low. I would also adjust the number of Vitiligo patient to reflect the 2-5 % prevalence in the US and the fact that Scenesse will target FP4-5. Still, the number of potential patients is a lot higher than what the author assumes. But I like his conservative approach and comprehensive analysis.
http://minussinus.de/clinuvel-unterbewertetes-pharmaunternehmen-startet-markteinfuehrung/
To follow KarinCA, click here then click "Follow This Member" under my photo.
Be kinder than necessary, for everyone you meet is fighting some kind of battle.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM